On March 22, Lbx Pharmacy Chain Joint Stock Company(603883) held a shareholders’ meeting in Changsha headquarters, and the company’s proposal to acquire the equity of Huairen dahealth was passed by a high vote of 95.41%. Upon completion of this transaction, Lbx Pharmacy Chain Joint Stock Company(603883) will hold 761199% equity of Huairen dahealth to realize holding.
It is understood that Huairen great health is the most influential retail chain drugstore in Western Hunan, with a sales volume of 1.402 billion yuan in 2020. Now it has more than 660 direct drugstores, which are distributed in Western Hunan regions such as Huaihua, Western Hunan Autonomous Prefecture, Shaoyang, Zhang Jia Jie Tourism Group Co.Ltd(000430) and Guizhou, ranking first in the total market share in Western Hunan.
At the shareholders’ meeting, Xie Zilong, the Lbx Pharmacy Chain Joint Stock Company(603883) chairman, said that the acquisition was a landmark event in the pharmaceutical retail industry and a benchmark for the company to develop the holding spark acquisition model. The merger of Huairen health will effectively fill the relatively blank area of the company’s marketing network coverage in Hunan and effectively form a regional joint force.
After the completion of the transaction, Lbx Pharmacy Chain Joint Stock Company(603883) will become the pharmaceutical retail chain enterprise with the largest number of stores in Hunan Province, ranking first in the number of stores in 7 of the 14 prefectures and cities in Hunan Province.
Xie Zilong also said that while improving the company’s performance, this transaction will greatly improve the company’s scale and procurement scale in the national pharmaceutical retail market, reduce procurement costs and improve the company’s overall profitability. In addition, the successful completion of the transaction also helps to improve the company’s competitiveness and brand reputation in the industry, which is of great significance to the company’s long-term development.
